Pulmonary coccidioidomycosis
ICD-10 B39.1 is a billable code used to indicate a diagnosis of pulmonary coccidioidomycosis.
Pulmonary coccidioidomycosis is a fungal infection caused by the inhalation of spores from the Coccidioides species, primarily C. immitis and C. posadasii. This condition is endemic to certain regions, particularly the southwestern United States, parts of Mexico, and Central and South America. The infection can manifest as a mild respiratory illness or progress to more severe pulmonary disease, particularly in immunocompromised individuals. Symptoms may include cough, chest pain, fever, and fatigue. In some cases, it can lead to chronic pulmonary conditions or disseminated disease affecting other organs. Diagnosis is typically confirmed through serological tests, culture, or histopathological examination. Treatment often involves antifungal medications such as fluconazole or itraconazole, especially in cases of severe or disseminated disease. The management of pulmonary coccidioidomycosis requires careful consideration of the patient's immune status, as those who are immunocompromised are at a higher risk for severe disease and complications.
Detailed patient history, including travel and exposure history, laboratory results, and treatment plans.
Patients presenting with respiratory symptoms after travel to endemic areas.
Consideration of co-morbid conditions that may affect treatment and outcomes.
Pulmonary function tests, imaging studies, and symptom assessments.
Patients with chronic cough and chest pain who have a history of exposure.
Documentation of lung imaging findings and response to treatment.
Used to confirm diagnosis in patients with respiratory symptoms.
Document the reason for testing and the patient's clinical presentation.
Infectious disease specialists may order this test more frequently.
Pulmonary coccidioidomycosis is primarily caused by inhaling spores from the Coccidioides fungus, which is found in certain geographic areas.
